Published in Genet Vaccines Ther on June 18, 2011
Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. Biomaterials (2014) 0.82
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol (2007) 168.76
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell (1985) 16.46
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. J Exp Med (1991) 3.30
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A (1993) 3.27
Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family. J Biol Chem (1996) 2.44
B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol (1995) 2.29
Expression of the macrophage-specific antigen F4/80 during differentiation of mouse bone marrow cells in culture. J Exp Med (1981) 2.25
Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family. J Biol Chem (1993) 2.10
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63
Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol (1997) 1.60
Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol (2005) 1.43
DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther (2007) 1.27
Inactivation of the F4/80 glycoprotein in the mouse germ line. Mol Cell Biol (2002) 1.18
B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol (2005) 1.12
The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun. J Biol Chem (1998) 1.05
Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol (2006) 1.03
Cloning of the murine beta5 integrin subunit promoter. Identification of a novel sequence mediating granulocyte-macrophage colony-stimulating factor-dependent repression of beta5 integrin gene transcription. J Biol Chem (1999) 1.01
Detection of promoter activity by flow cytometric analysis of GFP reporter expression. Nucleic Acids Res (2002) 1.01
Ensuring safety of DNA vaccines. Microb Cell Fact (2005) 1.00
Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum Gene Ther (2003) 0.99
Targeting lymphocyte co-stimulation: from bench to bedside. Autoimmunity (2010) 0.98
Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1997) 0.98
Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther (2007) 0.97
Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A (2006) 0.97
Driving gene expression specifically in dendritic cells. Adv Exp Med Biol (1997) 0.92
DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol (1998) 0.91
Immunization of the female genital tract with a DNA-based vaccine. Infect Immun (1998) 0.90
DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS One (2006) 0.90
Sp1/Sp3 and PU.1 differentially regulate beta(5) integrin gene expression in macrophages and osteoblasts. J Biol Chem (2000) 0.89
Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther (2001) 0.87
BCL2 protein expression parallels its mRNA level in normal and malignant B cells. Blood (2004) 0.87
Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. J Immunol (2001) 0.86
Functional analysis of the murine Emr1 promoter identifies a novel purine-rich regulatory motif required for high-level gene expression in macrophages. Genomics (2004) 0.85
Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. Vaccine (2009) 0.84
Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann Surg Oncol (1996) 0.83
Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. Gene Ther (2003) 0.83
Measurement of green fluorescent protein concentration in single cells by image analysis. Anal Biochem (2002) 0.83
Therapeutic effects of DNA vaccine on allergen-induced allergic airway inflammation in mouse model. Cell Mol Immunol (2006) 0.83
APC-targeted immunization for the treatment of HIV-1. Expert Rev Vaccines (2004) 0.81
Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication. Vaccine (2000) 0.80
Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivo. Arch Otolaryngol Head Neck Surg (2010) 0.80
Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization. Immunobiology (1999) 0.80
A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet (2004) 3.25
Enteroviruses in patients with acute encephalitis, uttar pradesh, India. Emerg Infect Dis (2009) 1.71
Genetic characterization of Bagaza virus (BAGV) isolated in India and evidence of anti-BAGV antibodies in sera collected from encephalitis patients. J Gen Virol (2009) 1.41
Detection and isolation of Japanese encephalitis virus from blood clots collected during the acute phase of infection. Am J Trop Med Hyg (2007) 1.18
Introduction of Japanese encephalitis virus genotype I, India. Emerg Infect Dis (2011) 1.13
Pathogenic and vaccine strains of Japanese encephalitis virus elicit different levels of human macrophage effector functions. Arch Virol (2012) 0.84
Delineation of an epitope on domain I of Japanese encephalitis virus Envelope glycoprotein using monoclonal antibodies. Virus Res (2011) 0.84
De novo identification of viral pathogens from cell culture hologenomes. BMC Res Notes (2012) 0.81
Temporal changes of Japanese encephalitits virus in different brain regions of rat. Indian J Med Res (2013) 0.79
Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes. Virus Res (2011) 0.77
Design and characterization of polytope construct with multiple B and TH epitopes of Japanese encephalitis virus. Virus Res (2012) 0.75
Japanese Encephalitis Presenting Without Cerebrospinal Fluid Pleocytosis. Pediatr Infect Dis J (2015) 0.75